Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists.
about
Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian ratAnatomy of Graft-induced Dyskinesias: Circuit Remodeling in the Parkinsonian StriatumEffects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian ratStriatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia.Animal models of Parkinson's disease: a gateway to therapeutics?MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.Triptolide protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats: implication for immunosuppressive therapy in Parkinson's disease.Abnormalities of Dopamine D3 Receptor Signaling in the Diseased Brain.Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptorsDifferential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
P2860
Q30484170-02969287-08DB-4002-B1FA-83102C517F00Q35589979-03C63368-52B3-4FC7-85EE-85A16DBB3C55Q35815701-B7B20C69-5FBB-42BC-B00D-C6F0231427C6Q36034592-EC78993B-8BD6-4197-81A5-6C030453E463Q36851672-27BA6225-B6A6-4385-BCF9-4AE0BFDA36E0Q36852272-35F4C5EB-9163-48DC-9BA6-9DCC03DB2AD9Q37103028-DFB53EAC-AD3E-45AF-9CCC-E317909A07C1Q37674269-C9466772-E31F-405B-AB43-17B4F4D917FBQ38155480-E74BDCB1-7E13-49C6-94EC-179CB053B0A7Q39906818-FBCDDEC0-13D3-4999-A8D8-4ADECD2F8C86Q41351319-06A244CD-6485-4E51-BD89-AF09661FED7CQ41456216-C1EF8D45-E37B-44B2-B0F0-BBEBB9B0F378Q42121362-1E45DEF3-04A3-4268-8580-E73FC41B62A9Q45928216-0195537D-B7B1-4C1E-9707-34A4E786F12C
P2860
Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists.
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Validation of the l-dopa-induc ...... ptor agonists and antagonists.
@ast
Validation of the l-dopa-induc ...... ptor agonists and antagonists.
@en
type
label
Validation of the l-dopa-induc ...... ptor agonists and antagonists.
@ast
Validation of the l-dopa-induc ...... ptor agonists and antagonists.
@en
prefLabel
Validation of the l-dopa-induc ...... ptor agonists and antagonists.
@ast
Validation of the l-dopa-induc ...... ptor agonists and antagonists.
@en
P1476
Validation of the l-dopa-induc ...... ptor agonists and antagonists.
@en
P2093
Eduardo M Torres
P356
10.1016/J.BRAINRESBULL.2004.10.011
P577
2004-12-18T00:00:00Z